when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ABBVIE · news · pharmadog

← back to ABBVIE

News mentioning ABBVIE

148 stories

Sep 3, 26AbbVie claims Phase 3 win for multiple myeloma drug etentamigendpoints

Sep 3, 26Psilocybin proves promising in neuropathic pain mouse studyfiercebiotech

Sep 3, 26AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialfiercebiotech

Sep 3, 26Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drugraps

Sep 1, 26Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyfiercebiotech

Aug 31, 26BMS’ neuro renaissance was built on back of Celgene mega-mergerbiospace

Aug 28, 26FDA green lights Priovant drug for rare skin diseasebiopharma dive

Aug 27, 26Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushfiercebiotech

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 26, 26Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debatefiercebiotech

Aug 25, 26After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech

Aug 25, 26China’s Haisco forms immunology biotech with up to $1.5B from American VCsbiospace

Aug 25, 26Massachusetts biopharma jobs, including R&D positions, fell in 2025: Reportbiospace

Aug 24, 26Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’biospace

Aug 19, 26Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analystsbiospace

Aug 19, 2611 companies hiring in New Jerseybiospace

Aug 19, 26Merck and Sarah Cannon team up to boost oncology trial efficiencyfiercebiotech

Aug 18, 26Merck and Sarah Cannon team up to boost oncology trial efficiencyfiercebiotech

Aug 12, 26With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentbiospace

Aug 11, 26AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinoisendpoints

Aug 11, 26STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and morestat

Aug 10, 26Sionna cystic fibrosis drug fails key trial, removing threat to Vertexbiopharma dive

Aug 10, 26STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and morestat

Aug 10, 26MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialfiercebiotech

Aug 10, 26Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertexfiercebiotech

Aug 10, 26As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorbiospace

Aug 7, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Aug 7, 26STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and morestat

Aug 7, 26Is the biotech capital of the world moving?stat

Aug 6, 26STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group assertsstat

← prevpage 3 of 5next →